Kenneth Cohen to Etoposide
This is a "connection" page, showing publications Kenneth Cohen has written about Etoposide.
Connection Strength
0.131
-
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Adv. 2025 Nov 11; 9(21):5665-5675.
Score: 0.057
-
No responses to oral etoposide in 15 patients with recurrent brain tumors. Med Pediatr Oncol. 2000 Jul; 35(1):80-2.
Score: 0.039
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.035